Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

Both Mounjaro and Zepbound are exclusive to Eli Lilly, but compounding pharmacies are permitted to make and sell copycat versions of such drugs when they’re in shortage. And in the nearly two ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its popular weight-loss drugs, Zepbound and Mounjaro. The drugmaker said it ...

Shares of Eli Lilly & Co. were headed for their worst ... citing slower-than-expected growth in sales of its diabetes and weight-loss drugs. “While the U.S. incretin market grew 45% compared ...

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Gift 5 articles to anyone you choose each month when you subscribe. Taxpayers would fund popular weight-loss drugs for people with severe obesity under a proposal from American pharmaceutical ...

The total includes about $3.5 billion for Mounjaro and $1.9 billion ... smaller rivals for share of the exploding weight loss and diabetes drug market. Eli Lilly is developing an obesity pill ...